

- Allergic conjunctivitis is one of the most common ophthalmic disorders worldwide, with symptoms resulting from mast cell degranulation and histamine release.
- Until recently, most available ocular treatment required twice-daily dosing for the prevention of ocular itching, the hallmark symptom of allergic conjunctivitis.
- This pooled analysis of two similarly designed randomized trials comprising a total of 284 subjects combines efficacy and safety findings after treatment with once-daily alcaftadine 0.25% versus olopatadine 0.2% for prevention of ocular itching associated with allergic conjunctivitis.
- At 16 hours post treatment instillation, alcaftadine 0.25% ophthalmic solution provided greater relief of ocular itching compared with olopatadine 0.2% ophthalmic solution, with a similar safety profile.
- Results support the use of alcaftadine 0.25% for the prevention of itching associated with allergic conjunctivitis.

This summary slide represents the opinions of the authors. Sponsorship for this study was funded by Allergan, Inc., Irvine, CA. Medical writing assistance for this study was provided by Kakuri M. Omari, PhD, of Evidence Scientific Solutions, Philadelphia, PA. For a full list of acknowledgments and conflicts of interest for all authors of this article, please see the full text online. Copyright © The Author(s) 2014. Creative Commons Attribution Noncommercial License (CC BY-NC).